These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8080984)

  • 21. A complete and durable response to denileukin diftitox in a patient with mycosis fungoides.
    Carretero-Margolis CD; Fivenson DP
    J Am Acad Dermatol; 2003 Feb; 48(2):275-6. PubMed ID: 12582402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rational therapy for cutaneous T-cell lymphomas in the 1990s. Fact or fancy?
    Bunn PA
    Arch Dermatol; 1995 May; 131(5):603-5. PubMed ID: 7537952
    [No Abstract]   [Full Text] [Related]  

  • 23. Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies.
    Duvic M; Geskin L; Prince HM
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):377-84. PubMed ID: 23770157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.
    Platanias LC; Ratain MJ; O'Brien S; Larson RA; Vardiman JW; Shaw JP; Williams SF; Baron JM; Parker K; Woodworth TG
    Leuk Lymphoma; 1994 Jul; 14(3-4):257-62. PubMed ID: 7950914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukins in the treatment of mycosis fungoides.
    Gerami P; Guitart J; Rosen S; Kuzel TM
    G Ital Dermatol Venereol; 2008 Feb; 143(1):55-8. PubMed ID: 18833051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
    Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
    Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Denileukin diftitox therapy for patients with tumour-stage mycosis fungoides.
    Assaf C
    Dermatol Clin; 2008 Jan; 26 Suppl 1():21-2. PubMed ID: 18405182
    [No Abstract]   [Full Text] [Related]  

  • 28. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.
    Prince HM; Duvic M; Martin A; Sterry W; Assaf C; Sun Y; Straus D; Acosta M; Negro-Vilar A
    J Clin Oncol; 2010 Apr; 28(11):1870-7. PubMed ID: 20212249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497.
    Kuzel TM; Li S; Eklund J; Foss F; Gascoyne R; Abramson N; Schwerkoske JF; Weller E; Horning SJ
    Leuk Lymphoma; 2007 Dec; 48(12):2397-402. PubMed ID: 17943599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma.
    Foss F; Demierre MF; DiVenuti G
    Blood; 2005 Jul; 106(2):454-7. PubMed ID: 15811959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Denileukin diftitox.
    Saxon M
    Clin J Oncol Nurs; 2000; 4(6):289, 293. PubMed ID: 11899329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/Sézary syndrome receiving placebo.
    Prince HM; Duvic M; Martin A; Sterry W; Assaf C; Straus DJ
    J Am Acad Dermatol; 2012 Nov; 67(5):867-75. PubMed ID: 22285675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Preclinical and clinical researches of Denileukin Diftitox (Genetical Recombination) (Remitoro
    Shiiba H; Takechi A; Asakura S; Kawaguchi T; Sato M
    Nihon Yakurigaku Zasshi; 2022; 157(5):376-382. PubMed ID: 36047157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Denileukin diftitox.
    Figgitt DP; Lamb HM; Goa KL
    Am J Clin Dermatol; 2000; 1(1):67-72; discussion 73. PubMed ID: 11702307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia.
    LeMaistre CF; Rosenblum MG; Reuben JM; Parkinson DR; Meneghetti CM; Parker K; Shaw JP; Deisseroth AB; Woodworth T
    Lancet; 1991 May; 337(8750):1124-5. PubMed ID: 1674015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene.
    Talpur R; Duvic M
    Clin Lymphoma Myeloma; 2006 May; 6(6):488-92. PubMed ID: 16796781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas.
    Talpur R; Duvic M
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):180-5. PubMed ID: 22521504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma.
    Marolleau JP; Baccard M; Flageul B; Rybojad M; Laroche L; Vérola O; Brandely M; Morel P; Gisselbrecht C
    Arch Dermatol; 1995 May; 131(5):574-9. PubMed ID: 7741545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-2 receptor-directed therapies for cutaneous lymphomas.
    Foss FM; Waldmann TA
    Hematol Oncol Clin North Am; 2003 Dec; 17(6):1449-58. PubMed ID: 14710895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
    Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
    Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.